ArticleCardiovascular diabetology2019
SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob
Article in Cardiovascular diabetology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed, 164 citations in OpenAlex.
- Dapagliflozin-induced integrated improvements in left ventricular diastole, endothelial function, and arterial load: a randomized clinical trial.Cardiovascular diabetology · 2026Trial
- Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report.Cardiovascular diabetology · 2022Trial
- Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes.Diabetes care · 2022 · on this mapTrial
- Trial
- Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial.Cardiovascular diabetology · 2021 · on this mapTrial
- Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial.Journal of the American Heart Association · 2021Trial
- Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial.Cardiovascular diabetology · 2020Trial
- The Role of SGLT2 Inhibitors in the Prevention of Type 2 Diabetes: A Narrative Review of Current Evidence.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Review
- Coronary microvascular dysfunction: a narrative review.Cardiovascular diagnosis and therapy · 2026Review
- Sweet relief: exploring mechanisms and therapeutic approaches of sodium-glucose cotransporter-2 inhibitors in cardiovascular-kidney metabolic syndrome.Cardiovascular diabetology · 2026Review
- Coronary Microvascular Dysfunction in Cardiomyopathies: Insights on Clinical and Prognostic Roles.Reviews in cardiovascular medicine · 2026Review
- Kuanxiong aerosol protects against coronary microvascular dysfunction through improving angiogenesis via HIF-1α-ITGAX axis.Frontiers in pharmacology · 2026Article
- The clinical efficacy and safety of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials.Annals of medicine and surgery (2012) · 2025Review
- Effects of SGLT2 inhibitors on angiography-derived coronary microcirculatory resistance and clinical outcomes in patients with coronary heart disease and type 2 diabetes: A cohort study.Diabetology & metabolic syndrome · 2025Article
- Prevalence and importance of coronary microvascular dysfunction in patients with heart failure and reduced or mildly reduced ejection fraction.Open heart · 2025Article
- Underpinnings of heart failure with preserved ejection fraction in women - From prevention to improving function. A co-publication with the American Journal of Preventive Cardiology and the Journal of Cardiac Failure.American journal of preventive cardiology · 2025Article
- Heart failure with preserved ejection fraction and obesity: emerging metabolic therapeutic strategies.Diabetology & metabolic syndrome · 2025Review
- Matrine alleviates coronary microvascular dysfunction in ischemia with non-obstructive coronary artery disease mice induced by advanced glycation end products inhibition of the reactive oxygen species-mediated endoplasmic reticulum stress in cardiac microvascular endothelial cells.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Structural and functional characterization of the cardiac mitochondria-associated reticular membranes in theJournal of molecular and cellular cardiology plus · 2025Article
- Cardiometabolic Phenotype in HFpEF: Insights from Murine Models.Biomedicines · 2025Review
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSodium-glucose cotransporter 2 inhibitors (SGLT2i) is the first class of anti-diabetes treatment that reduces mortality and risk for hospitalization due to heart failure. In clinical studies it has been shown that SGLT2i's promote a general shift to fasting state metabolism characterized by reduced body weight and blood glucose, increase in glucagon/insulin ratio and modest increase in blood ketone levels. Therefore, we investigated the connection between metabolic changes and cardiovascular function in the ob/ob
methodsLean, ob/ob
resultsSodium-glucose cotransporter 2 inhibitors treatment of ob/ob
conclusionsSodium-glucose cotransporter 2 inhibitors treatment of ob/ob
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.